Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 40
Filtrar
Más filtros

País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
3.
Lipids Health Dis ; 17(1): 145, 2018 Jun 20.
Artículo en Inglés | MEDLINE | ID: mdl-29925393

RESUMEN

BACKGROUND: The beneficial effects in lipid profiles after obesity surgery might be associated with the decrease in cardiovascular risk. However, direct comparison between different surgical techniques has not been extensively performed. METHODS: In the present study we compare 20 obese women submitted to laparoscopic Roux en Y gastric bypass (RYGB) with 20 women submitted to sleeve gastrectomy (SG). Twenty control women matched for age and baseline cardiovascular risk were also included. Both patients and controls were followed up for 1 year after surgery or conventional treatment with diet and exercise, respectively. Lipid profiles were measured at baseline, 6 and 12 months later. Carotid intima-media thickness was measured by ultrasonography at baseline and at the end of the study. RESULTS: Women submitted to bariatric surgery showed a decrease in total cholesterol, triglycerides, oxidized-LDL and ApoB, and an increase in HDL and ApoA concentrations that occurred regardless of the surgical procedure. LDL concentrations, however, decreased only after RYGB whereas Lp(a) showed no changes. We did not observe any correlation between the changes in serum lipid concentrations and those in carotid intima-media thickness. CONCLUSIONS: Sleeve gastrectomy and gastric bypass induce a similar beneficial effect on serum lipids in women with high cardiovascular risk 1 year after surgery.


Asunto(s)
Gastrectomía/métodos , Derivación Gástrica , Gastroplastia/métodos , Obesidad Mórbida/sangre , Obesidad Mórbida/cirugía , Adulto , Apolipoproteínas A/sangre , Apolipoproteínas B/sangre , Restricción Calórica , Enfermedades Cardiovasculares/diagnóstico por imagen , Enfermedades Cardiovasculares/prevención & control , Arterias Carótidas/diagnóstico por imagen , Grosor Intima-Media Carotídeo , Estudios de Casos y Controles , Ejercicio Físico , Femenino , Estudios de Seguimiento , Humanos , Lipoproteínas HDL/sangre , Lipoproteínas LDL/sangre , Persona de Mediana Edad , Obesidad Mórbida/dietoterapia , Obesidad Mórbida/patología , Riesgo , Triglicéridos/sangre , Ultrasonografía
5.
Nutr Metab Cardiovasc Dis ; 24(3): 328-35, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24462043

RESUMEN

BACKGROUND AND AIMS: Reduction of cardiovascular risk with high consumption of fish in diet is still a matter of debate, and concerns about heavy metal contamination have limited consumption of oily fish. We aimed to evaluate the effect of regular ingestion of white fish on cardiovascular risk factors in patients with metabolic syndrome. METHODS AND RESULTS: Multicenter randomized crossover clinical trial including 273 individuals with metabolic syndrome. An 8-week only-one dietary intervention: 100 g/d of white fish (Namibia hake) with advice on a healthy diet, compared with no fish or seafood with advice on a healthy diet. Outcomes were lipid profile, individual components of the metabolic syndrome, serum insulin concentrations, homeostasis model of insulin resistance, serum C-reactive protein and serum fatty acid levels. We found a significant lowering effect of the intervention with white fish on waist circumference (P < 0.001) and diastolic blood pressure (P = 0.014). A significant lowering effect was also shown after the dietary intervention with fish on serum LDL concentrations (P = 0.048), whereas no significant effects were found on serum HDL or triglyceride concentrations. A significant rise (P < 0.001) in serum EPA and DHA fatty acids was observed following white fish consumption. Overall adherence to the intervention was good and no adverse events were found. CONCLUSION: In individuals with metabolic syndrome, regular consumption of hake reduces LDL cholesterol concentrations, waist circumference and blood pressure components of the metabolic syndrome. CLINICAL TRIAL REGISTRY: White Fish for Cardiovascular Risk Factors in Patients with Metabolic Syndrome Study, Registered under ClinicalTrials.gov Identifier: NCT01758601.


Asunto(s)
Enfermedades Cardiovasculares/sangre , Carne , Síndrome Metabólico/sangre , Alimentos Marinos , Anciano , Animales , Presión Sanguínea/efectos de los fármacos , Índice de Masa Corporal , Proteína C-Reactiva/metabolismo , Enfermedades Cardiovasculares/prevención & control , HDL-Colesterol/sangre , LDL-Colesterol/sangre , Dieta , Ácidos Grasos/sangre , Femenino , Peces , Humanos , Insulina/sangre , Resistencia a la Insulina , Masculino , Síndrome Metabólico/dietoterapia , Persona de Mediana Edad , Factores de Riesgo , Resultado del Tratamiento , Triglicéridos/sangre , Circunferencia de la Cintura
6.
J Endocrinol Invest ; 36(4): 227-32, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22732238

RESUMEN

BACKGROUND AND AIM: Male hypogonadism has been linked to obesity and diabetes. We aimed to study the association of changes in insulin sensitivity and testosterone levels in severe obese patients submitted to bariatric surgery. SUBJECTS AND METHODS: Prospective intervention study with twenty consecutive patients who underwent bariatric surgery studied before and after significant weight loss. Serum testosterone, SHBG, fasting glucose, and insulin were measured among others. Free testosterone was calculated with the Vermeulen formula and insulin sensitivity with the homeostatic model assessment (HOMA). RESULTS: At baseline, thirteen patients had low total testosterone levels, whereas eight of these patients also had free testosterone levels below the reference range obtained from the control group. After bariatric surgery total testosterone, SHBG, and free testosterone significantly increased and achieved normal values in all evaluated patients. Insulin sensitivity improved in all of them. Multivariate linear regression showed that changes in fasting glucose (ß=-1.868, p=0.001), insulin (ß=-3.782, p=0.001), weight (ß=-0.622, p=0.002), and SHBG (ß=-0.635, p=0.022) were associated with changes in free testosterone (adjusted R2=0.936, F=26.613, p=0.001). When insulin resistance calculated by HOMA was in the model instead of insulin and glucose, it also was associated (ß=-3.488, p=0.008) with free testosterone (adjusted R2=0.821, F=11.111, p=0.005). CONCLUSIONS: Circulating tes tos terone in obese men increases after bariatric surgery in parallel with an improvement in insulin sensitivity.


Asunto(s)
Cirugía Bariátrica , Resistencia a la Insulina , Obesidad/sangre , Obesidad/cirugía , Testosterona/sangre , Adulto , Cirugía Bariátrica/rehabilitación , Glucemia/análisis , Humanos , Hipogonadismo/sangre , Hipogonadismo/etiología , Hipogonadismo/cirugía , Insulina/sangre , Resistencia a la Insulina/fisiología , Masculino , Persona de Mediana Edad , Obesidad/complicaciones , Periodo Posoperatorio , Globulina de Unión a Hormona Sexual/análisis , Regulación hacia Arriba
7.
Rev Clin Esp (Barc) ; 222(8): 458-467, 2022 10.
Artículo en Inglés | MEDLINE | ID: mdl-35597729

RESUMEN

AIM: This study evaluated prevalence of primary bilateral macronodular adrenal hyperplasia (PBMAH). It also analyzed the differential phenotype of patients with PBMAH compared to other bilateral adrenal lesions that do not meet the definition of PBMAH. METHODS: We reviewed the medical records of 732 patients diagnosed with an adrenal incidentaloma at our center. Ninety-eight patients with subclinical hypercortisolism were included in the analysis. We defined PBMAH as the presence of plasma cortisol > 1.8 µg/dL after an over-night 1-mg dexamethasone test, bilateral adrenal hyperplasia, and bilateral adrenal nodules > 1 cm. RESULTS: A total of 31 patients had PBMAH. Patients with PBMAH showed greater prevalence of autonomous cortisol secretion (plasma cortisol > 5.0 µg/dL after an overnight 1-mg dexamethasone test) than patients without PBMAH (OR 4.1, 95%CI 1.38-12.09, p = 0.010). Tumor size and total adenomatous mass were significantly greater in patients with PBMAH compared to patients without PBMAH (30.2 ±â€¯12.16 vs. 24.3 ±â€¯8.47 mm, p = 0.010 and 53.9 ±â€¯20.8 vs. 43.3 ±â€¯14.62 mm, p = 0.023), respectively. A greater proportion of patients with PBMAH had diabetes compared to patients without PBMAH (45.2% vs. 25.4%, p = 0.05). CONCLUSION: PBMAH is present in one-third of patients with adrenal incidentaloma and subclinical hypercortisolism. Patients with PBMAH showed greater autonomous cortisol secretion, bigger tumor size, and higher rates of diabetes than those without PBMAH.


Asunto(s)
Neoplasias de las Glándulas Suprarrenales , Síndrome de Cushing , Neoplasias de las Glándulas Suprarrenales/diagnóstico , Neoplasias de las Glándulas Suprarrenales/epidemiología , Síndrome de Cushing/epidemiología , Dexametasona , Humanos , Hidrocortisona , Hiperplasia , Fenotipo , Prevalencia
8.
Clin Transl Oncol ; 24(1): 112-126, 2022 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-34363594

RESUMEN

PURPOSE: Malnutrition is a common problem among pancreatic cancer (PC) patients that negatively impacts on their quality of life (QoL) and clinical outcomes. The main objective of this consensus is to address the role of Medical Nutrition Therapy (MNT) into the comprehensive therapeutic management of PC patients. METHODS: A Spanish multidisciplinary group of specialists from the areas of Medical Oncology; Radiation Oncology; Endocrinology and Nutrition; and General Surgery agreed to assess the role of MNT as part of the best therapeutic management of PC patients. RESULTS: The panel established different recommendations focused on nutritional screening and nutritional screening tools, MNT strategies according to PC status, and MNT in palliative treatment. CONCLUSIONS: There is an unmet need to integrate nutritional therapy as a crucial part of the multimodal care process in PC patients. Health authorities, health care professionals, cancer patients, and their families should be aware of the relevance of nutritional status and MNT on clinical outcomes and QoL of PC patients.


Asunto(s)
Desnutrición/dietoterapia , Desnutrición/etiología , Terapia Nutricional , Neoplasias Pancreáticas/complicaciones , Vías Clínicas , Humanos , Estado Nutricional
9.
Clin Endocrinol (Oxf) ; 75(2): 184-8, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21521304

RESUMEN

AIMS: To evaluate serum levels of osteocalcin (OC), procollagen type 1 N-terminal propeptide (P1PN) and beta-CrossLaps (beta-CTx) in obese subjects and their relationship with glucose metabolism parameters. SUBJECTS: Sixty-four obese patients classified according to their glucose tolerance. DESIGN: Case-control study. MEASUREMENTS: A 75-g oral glucose tolerance test was performed with determinations of glucose and insulin between 0 and 120 min. Serum concentrations of OC, P1PN and beta-CTx were quantified in baseline samples. RESULTS: Patients with type 2 diabetes (T2D, n = 24) exhibited OC serum levels (2·6 ± 1·0 nm) significantly lower than those found in subjects with normal glucose tolerance (NGT, n = 20, 3·9 ± 1·5 nm, P < 0·01). We found no significant differences in P1NP and beta-CTX levels among patients with NGT, prediabetes and T2D. Multiple regression analysis showed that serum OC concentration, but not P1NP or beta-CTx levels, was independently related to 2-h plasma glucose. CONCLUSION: Obese patients with T2D showed significantly reduced levels of OC in comparison with patients with lower degrees of glucose tolerance derangement. Our results also suggest that OC was the only bone marker independently related to the degree of glucose metabolism derangement in these patients.


Asunto(s)
Colágeno Tipo I/sangre , Colágeno/sangre , Prueba de Tolerancia a la Glucosa , Obesidad/sangre , Osteocalcina/sangre , Fragmentos de Péptidos/sangre , Glucemia/análisis , Estudios de Casos y Controles , Diabetes Mellitus Tipo 2 , Humanos , Procolágeno/sangre , Precursores de Proteínas
10.
J Endocrinol Invest ; 31(10): 845-50, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19092286

RESUMEN

Secondary hyperparathyroidism (SH) is a frequent metabolic complication of bariatric surgery. Around 70%of patients who undergo biliopancreatic diversion (BPD) have this complication in the long term. The aim of this study was to evaluate the relative influence of vitamin D deficiency and calcium malabsorption in the development of SH in patients who underwent BPD. We reviewed the mean values of PTH throughout the post-operative follow-up and of related biochemical data (25-hydroxyvitamin D, calcium, magnesium) of 121 patients who underwent BPD at our institute from November 1996 to November 2004 (mean follow-up 66 months). Mean PTH correlated negatively with mean 25-hydroxyvitamin D (r=-0.27, p=0.003) and with urinary calcium(r=-0.19, p=0.047), and positively with age (r=0.22, p=0.018). However, a high mean PTH was found in 48.7% patients with mean 25-hydroxyvitamin D >or=30 ng/ml and in 80.0% patients with mean 25-hydroxyvitamin D between 20 and 30 ng/ml. The mean PTH was normal in 5 patients without calcium supplements at present, and progressively increased in parallel to the calcium dose in the rest of patients, although mean 25-hydroxyvitamin D levels were not related to the calcium dose. Our data suggest that individual differences in active and/or passive calcium absorption determine intractable SH after BPD in around half of the patients who have normal levels of 25-hydroxyvitamin D and in 80% of patients with 25-hydroxyvitamin D levels between 20 and 30 ng/ml after BPD, worsening with age.


Asunto(s)
Desviación Biliopancreática/efectos adversos , Calcio/metabolismo , Hiperparatiroidismo Secundario/etiología , Síndromes de Malabsorción/complicaciones , Deficiencia de Vitamina D/complicaciones , Adulto , Anciano , Cirugía Bariátrica/efectos adversos , Calcio/orina , Femenino , Humanos , Magnesio/sangre , Masculino , Menopausia , Persona de Mediana Edad , Obesidad Mórbida/cirugía , Hormona Paratiroidea/metabolismo , Factores Sexuales , Vitamina D/análogos & derivados , Vitamina D/sangre
11.
12.
Clin. transl. oncol. (Print) ; 24(1): 112-126, enero 2022. graf
Artículo en Inglés | IBECS (España) | ID: ibc-203420

RESUMEN

PurposeMalnutrition is a common problem among pancreatic cancer (PC) patients that negatively impacts on their quality of life (QoL) and clinical outcomes. The main objective of this consensus is to address the role of Medical Nutrition Therapy (MNT) into the comprehensive therapeutic management of PC patients.MethodsA Spanish multidisciplinary group of specialists from the areas of Medical Oncology; Radiation Oncology; Endocrinology and Nutrition; and General Surgery agreed to assess the role of MNT as part of the best therapeutic management of PC patients.ResultsThe panel established different recommendations focused on nutritional screening and nutritional screening tools, MNT strategies according to PC status, and MNT in palliative treatment.ConclusionsThere is an unmet need to integrate nutritional therapy as a crucial part of the multimodal care process in PC patients. Health authorities, health care professionals, cancer patients, and their families should be aware of the relevance of nutritional status and MNT on clinical outcomes and QoL of PC patients.


Asunto(s)
Humanos , Ciencias de la Salud , 52503 , Desnutrición , Neoplasias Pancreáticas , Oncología Médica , Calidad de Vida , Carcinoma Ductal Pancreático
13.
Nutr Hosp ; 21(4): 552-5, 2006.
Artículo en Español | MEDLINE | ID: mdl-16913216

RESUMEN

BACKGROUND: Lipodystrophy is a frequent disorder among patients with human immunodeficiency virus (HIV) infection, characterized by a loss of adipose tissue from the extremities, gluteal region and face, with excess fat in the neck and abdominal region. Metabolic abnormalities such as hyperlipidaemia and diabetes mellitus frequently coexist, posing these patients to an increased cardiovascular risk. Drug therapy may improve some of these metabolic disturbances, but to date there are no treatments for lipodystrophy with proven benefit. CASE REPORT: A 42-year-old man with HIV lipodystrophy was started on a standard low caloric diet with <30% of total fat and <10% of saturated fat, together with rosiglitazone 8 mg daily. After five months of treatment, given that lipodystrophic features and dyslipidaemia were still present in our patient, we tried to further improve therapeutic results by eucaloric substitution of medium chain triglycerides for dietary long chain fatty acids. Three months later, a dramatic change in body composition was shown with an increase in lean mass and a decrease in fat mass, together with an improvement in lipid profile. CONCLUSION: Eucaloric substitution of medium chain triglycerides for dietary long chain fatty acids may produce therapeutic benefits in HIV lipodystrophy.


Asunto(s)
Grasas de la Dieta/administración & dosificación , Síndrome de Lipodistrofia Asociada a VIH/dietoterapia , Adulto , Composición Corporal , Dislipidemias/dietoterapia , Ingestión de Energía , Ácidos Grasos Insaturados/administración & dosificación , Síndrome de Lipodistrofia Asociada a VIH/tratamiento farmacológico , Humanos , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/uso terapéutico , Masculino , Rosiglitazona , Tiazolidinedionas/administración & dosificación , Tiazolidinedionas/uso terapéutico , Factores de Tiempo , Resultado del Tratamiento , Triglicéridos/administración & dosificación
14.
Nutr Hosp ; 21(6): 699-703, 2006.
Artículo en Español | MEDLINE | ID: mdl-17147069

RESUMEN

Obesity has become epidemic in Western countries. From clinical practice, obestity may be considered as a disease characterized by an excess of body fat mass, but patients usually demonstrate different responses to the same therapeutic strategy. It could be possible that the latter may be a consecuence of different pathophysiological factors among obese patients. Therefore, a detailed and thorough phenotyping of patients may enable clinitians to establish groups of patients that may respond in a homogeneous and effective way to a specific treatment for obesity. However, this type of approach can be especially time-consuming and may increase costs. In this study we describe the "PROBESCI" strategy, which is a novel system of studying the obese patient at the first visit, performed in groups of patients, aimed to the collection and analysis of data in order to categorize phenotypic profiles which may achive homogeneous responses to a specific therapy. We also analyze the costs of this new strategy compared to those of an individual consultation, showing a decrease of 58% for the first visit, and of 21% of the total costs throughout treatment.


Asunto(s)
Costos de la Atención en Salud , Obesidad/terapia , Visita a Consultorio Médico/economía , Adulto , Costos y Análisis de Costo , Humanos , Persona de Mediana Edad , Obesidad/economía , Evaluación de Programas y Proyectos de Salud , Derivación y Consulta/economía , Derivación y Consulta/organización & administración
15.
Endocr Relat Cancer ; 10(4): 601-10, 2003 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-14713270

RESUMEN

We studied the psychological performance and the quality of life in patients with differentiated thyroid carcinoma, either during treatment with chronic suppressive doses of levothyroxine, or during the withdrawal of levothyroxine needed to perform whole-body scanning with radioactive iodine, with those of appropriate healthy controls. Eighteen women with differentiated thyroid carcinoma and 18 euthyroid age-matched healthy women were recruited. Patients were studied the day before levothyroxine withdrawal (when in chronic mild or subclinical hyperthyroidism), 4-7 days later (when most patients had normal serum free thyroxine and free triiodothyronine levels), and the day before scanning (when in profound hypothyroidism). Controls were studied at one time point. When compared with controls, patients presented with impairment of several indexes during chronic suppressive levothyroxine therapy (total score, emotional, sleep, energy and social of the Nottingham Health Profile; mental health, general health and social function of the SF-36, and total score on Wais Digit Span; P<0.05 for all comparisons). Also, quality of life indexes (19 of 21 scores), cognitive tests (6 of 12 scores), and affective and physical symptoms visual mental scales (18 of 19) worsened during profound hypothyroidism (P<0.05 for all comparisons). Quality of life and cognitive performance were almost comparable with those of euthyroid controls when most patients had normal free thyroxine and triiodothyronine levels. In conclusion, quality of life and psychometric functionality in patients with differentiated thyroid carcinoma is not only affected by withdrawal of levothyroxine but also by long-term treatment with supraphysiological doses of levothyroxine.


Asunto(s)
Calidad de Vida , Neoplasias de la Tiroides/psicología , Adulto , Cognición/efectos de los fármacos , Potenciales Evocados Auditivos del Tronco Encefálico/efectos de los fármacos , Potenciales Evocados Visuales/efectos de los fármacos , Femenino , Humanos , Persona de Mediana Edad , Reflejo Anormal/efectos de los fármacos , Estadísticas no Paramétricas , Neoplasias de la Tiroides/sangre , Neoplasias de la Tiroides/tratamiento farmacológico , Tirotropina/sangre , Tiroxina/sangre , Tiroxina/uso terapéutico , Triyodotironina/sangre
16.
J Pediatr Endocrinol Metab ; 14(1): 103-6, 2001 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11220698

RESUMEN

We describe a patient with short stature more than that expected for non-treated congenital adrenal hyperplasia due to nonclassic 21-hydroxylase deficiency with deletions in the long arm of the Y chromosome including the CGY gene and the AZF subregions.


Asunto(s)
Estatura , Eliminación de Gen , Hipogonadismo/genética , Aberraciones Cromosómicas Sexuales , Cromosoma Y , Adolescente , Hiperplasia Suprarrenal Congénita/complicaciones , Hiperplasia Suprarrenal Congénita/enzimología , Criptorquidismo/complicaciones , Heterocigoto , Humanos , Hipogonadismo/complicaciones , Cariotipificación , Masculino , Reacción en Cadena de la Polimerasa , Pubertad Precoz/genética , Esteroide 21-Hidroxilasa/genética
18.
An Med Interna ; 18(3): 152-60, 2001 Mar.
Artículo en Español | MEDLINE | ID: mdl-11594183

RESUMEN

Leptin is a protein that has been identified three years ago, but its role, or at least its deficiency, was suspected from 1950. Dickie and coworkers reported the appearance of a mutant rat in one of their colonies with morbid obesity. The genetic defect was autosomal recessive and was manifested early in life. In December 1994, the gen ob was cloned, which stated the first step for the later identification of the gen product leptin, as a protein of 167 aminoacids expressed in adipose tissue. Since then, leptin has been implicated in many neuroendocrine regulatory pathways. The recent research in leptin roles worth an update review, and so its current and future clinical relevance.


Asunto(s)
Leptina/fisiología , Animales , Enfermedades del Sistema Endocrino/metabolismo , Hormona del Crecimiento/fisiología , Humanos , Sistema Hipotálamo-Hipofisario/fisiología , Obesidad/etiología , Páncreas/fisiología , Reproducción/fisiología , Glándula Tiroides/fisiología , Hormonas Tiroideas/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA